In:
AIDS Research and Treatment, Hindawi Limited, Vol. 2012 ( 2012), p. 1-6
Abstract:
Background . Nevirapine- (NVP-) based antiretroviral therapy (ART) and artesunate-amodiaquine are frequently coprescribed in areas of HIV and malaria endemicity. We explored the impact of this practice on artesunate and dihydroartemisinin pharmacokinetics. Methods . We conducted a parallel-group pharmacokinetic comparison between HIV-infected patients receiving NVP-based ART ( n = 10 ) and ART-naive controls ( n = 11 ). Artesunate-amodiaquine 200/600 mg was given daily for three days. Measurement of drug concentrations occurred between 0 and 96 hours after the final dose. Pharmacokinetic parameters were determined using noncompartmental analysis. Results . Comparing the NVP group to controls, clearance of artesunate was reduced 50% (1950 versus 2995 L/h; P = 0.03 ), resulting in a 45% increase in the AUC 0-96 (105 versus 69 ug ∗ hr/L; P = 0.02 ). The half-life of dihydroartemisinin was shorter in the NVP group (1.6 versuss 3.2 h; P = 0.004 ), but other dihydroartemisinin pharmacokinetic parameters were unchanged. A lower conversion of artesunate to dihydroartemisinin was observed in the NVP group (dihydroartemisinin: artesunate AUC 0-96 = 5.6 versuss 8.5 in NVP and control groups, respectively, P = 0.008 ). Conclusion . Although NVP-containing ART impacted some pharmacokinetic parameters of artesunate and dihydroartemisinin, overall exposure was similar or better in the NVP group.
Type of Medium:
Online Resource
ISSN:
2090-1240
,
2090-1259
Language:
English
Publisher:
Hindawi Limited
Publication Date:
2012
detail.hit.zdb_id:
2573930-X
Permalink